| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | OX40; ACT35; CD134; IMD16; TXGP1L |
| WB Predicted band size | 29 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human TNFRSF4 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于TNFRSF4(OX40)抗体的代表性文献，信息基于公开发表的研究整理：
---
1. **文献名称**：*Targeting OX40 in cancer immunotherapy*
**作者**：Weinberg AD, et al.
**摘要**：探讨了抗TNFRSF4(OX40)抗体在肿瘤免疫治疗中的作用，通过激活OX40信号增强T细胞抗肿瘤反应，抑制肿瘤生长，并在临床前模型中验证其疗效。
---
2. **文献名称**：*OX40 agonist antibodies in combination with radiotherapy enhance antitumor immune responses*
**作者**：Gough MJ, et al.
**摘要**：研究OX40激动型抗体联合放射治疗的协同效应，发现其能显著增强肿瘤微环境中T细胞的浸润和功能，延长小鼠模型生存期。
---
3. **文献名称**：*Distinct roles of OX40 signals in regulatory T cell differentiation and autoimmunity*
**作者**：Sugamura K, et al.
**摘要**：分析了OX40抗体对调节性T细胞(Treg)和效应T细胞的双向调控作用，揭示其在自身免疫疾病和癌症中的潜在治疗平衡策略。
---
(注：以上文献标题和内容为领域内典型研究方向示例，具体文献需通过PubMed或学术数据库检索确认。)
TNFRSF4 (tumor necrosis factor receptor superfamily member 4), also known as OX40 or CD134. is a co-stimulatory receptor primarily expressed on activated CD4+ and CD8+ T cells. It belongs to the TNF receptor family and interacts with its ligand OX40L (CD252), a TNF superfamily protein, to amplify T-cell activation, survival, and effector functions. This signaling axis plays a critical role in sustaining immune responses, particularly in chronic inflammation, autoimmune disorders, and antitumor immunity.
Antibodies targeting TNFRSF4 are widely used in research to modulate T-cell activity. Antagonistic antibodies block OX40-OX40L interactions, suppressing excessive T-cell activation, making them potential therapeutics for autoimmune diseases (e.g., rheumatoid arthritis, multiple sclerosis) and graft-versal-host disease. Conversely, agonistic antibodies enhance OX40 signaling to boost T-cell proliferation and cytokine production, which is being explored in cancer immunotherapy to overcome immune checkpoint resistance.
Structurally, TNFRSF4 antibodies typically recognize extracellular domains of the receptor, influencing downstream pathways like NF-κB and PI3K-Akt. Their therapeutic potential is underscored by clinical trials evaluating both antagonistic and agonistic formats. However, context-dependent effects require careful optimization to balance pro-inflammatory and immunosuppressive outcomes. Research continues to refine antibody specificity, isotype selection, and combination strategies with other immunomodulators.
×
